{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:34:54Z","timestamp":1792197294694,"version":"4.4.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Rheumatoid arthritis (RA) primarily affects the joints but can also affect multiple organs and profoundly impacts patients\u2019 ability to carry out daily activities, mental health, and life expectancy. Current treatments for RA are limited in terms of duration, efficacy, and adverse effects. PD-L1 is a checkpoint protein that plays important roles in immune regulation and has been implicated in the initiation and progression of multiple autoimmune diseases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>In a previous study, we demonstrated that intra-articular injection with adeno-associated virus (AAV) vectors encoding wild type PD-L1 improved local inflammation in the joint in the collagen-induced arthritis (CIA) mouse model of RA. To further improve efficacy, we explored AAV-mediated delivery of the soluble PD-L1 (sPD-L1) to CIA mice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Result<\/jats:title><jats:p>After intra-articular injection of AAV6 vectors expressing the optimal isoform of sPD-L1 (shPD-L1), more potency was observed when compared to wild type PD-L1, with a lower dose of AAV6\/shPD-L1 needed for arthritis improvement. To study the therapeutic effect of systemic expression of sPD-L1, we administered AAV8\/shPD-L1 gene therapy in CIA mice via retro-orbital injection and found significant improvements in joint inflammation and paw swelling, exhibiting similar phenotypes to that in na\u00efve mice. The levels of total immunoglobulin and anti-collagen specific antibodies were lower in AAV8\/shPD-L1 treated CIA mice than those in controls. The levels of pro-inflammatory cytokines in blood were also significantly decreased in shPD-L1 treated mice. Additionally, T cell apoptosis rates in the spleen showed a 2-fold increase in treated mice. Finally, we investigated the therapeutic effect of AAV\/shPD-L1 via intramuscular injection. After injection of AAV6\/shPD-L1, decreased paw swelling, reduced joint inflammation, and lower levels of pro-inflammatory cytokines in blood were achieved. The therapeutic effect of shPD-L1 was dose dependent via intramuscular treatment with AAV vectors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In conclusion, the findings in this study suggest that intra-articular injection of AAV vectors encoding sPD-L1 results in greater therapeutic benefit on arthritis, and systemic AAV\/sPD-L1 is able to block the development of inflammatory arthritis with inhibition of the systemic immune response, underlining the potential of gene therapy with systemic delivery of shPD-L1 via AAV vectors in RA.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1527858","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T05:12:47Z","timestamp":1738559567000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Secreted PD-L1 alleviates inflammatory arthritis in mice through local and systemic AAV gene therapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Wenjun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjiang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariana","family":"La Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eveline Y.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Loeser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/cells9040880","article-title":"Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis","volume":"9","author":"Lin","year":"2020","journal-title":"Cells"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2018.07.004","article-title":"Methotrexate mechanism in treatment of rheumatoid arthritis","volume":"86","author":"Friedman","year":"2019","journal-title":"Joint Bone Spine"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2012.03.011","article-title":"American College of Rheumatology, European League Against Rheumatism. My treatment approach to rheumatoid arthritis","volume":"87","author":"Davis","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2015-000133","article-title":"Risk of gastrointestinal bleeding and cardiovascular events due to NSAIDs in the diabetic elderly population","volume":"3","author":"Kim","year":"2015","journal-title":"BMJ Open Diabetes Res Care"},{"key":"B5","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jamadermatol.2020.4968","article-title":"Association of potent and very potent topical corticosteroids and the risk of osteoporosis and major osteoporotic fractures","volume":"157","author":"Egeberg","year":"2021","journal-title":"JAMA Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330302","article-title":"Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis","volume":"33","author":"Arend","year":"1990","journal-title":"Arthritis Rheumatism"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2147\/tcrm.2006.2.issue-2","article-title":"Rituximab and its potential for the treatment of rheumatoid arthritis","volume":"2","author":"Bryant","year":"2006","journal-title":"Ther Clin Risk Manage"},{"key":"B8","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13075-015-0731-1","article-title":"Abatacept decreases disease activity in a absence of CD4(+) T cells in a collagen-induced arthritis model","volume":"17","author":"Jansen","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21239067","article-title":"Effects of biological therapies on molecular features of rheumatoid arthritis","volume":"21","author":"Lopez-Pedrera","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B10","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.clinthera.2011.05.044","article-title":"Use of biologics in rheumatoid arthritis: current and emerging paradigms of care","volume":"33","author":"Curtis","year":"2011","journal-title":"Clin Ther"},{"key":"B11","article-title":"An overview of the extraarticular involvement in rheumatoid arthritis and its management","volume":"8","author":"Das","year":"2017","journal-title":"J Pharmacol Pharmacother"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1038\/s41467-018-04313-6","article-title":"STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion","volume":"9","author":"Hsu","year":"2018","journal-title":"Nat Commun"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1116084\/full","article-title":"Intra-articular delivery of AAV vectors encoding PD-L1 attenuates joint inflammation and tissue damage in a mouse model of rheumatoid arthritis","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2022.08.040","article-title":"Long-acting formulation strategies for protein and peptide delivery in the treatment of PSED","volume":"350","author":"Garkal","year":"2022","journal-title":"J Controlled Release"},{"key":"B15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s11095-020-02844-6","article-title":"Microneedle mediated transdermal delivery of protein, peptide and antibody based therapeutics: current status and future considerations","volume":"37","author":"Kirkby","year":"2020","journal-title":"Pharm Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1084\/jem.20180870","article-title":"Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non\u2013small cell lung cancer","volume":"216","author":"Gong","year":"2019","journal-title":"J Exp Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.153323","article-title":"Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation","volume":"7","author":"Sagawa","year":"2022","journal-title":"JCI Insight"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.3390\/cancers13123034","article-title":"Soluble programmed death ligand-1 (sPD-L1): A pool of circulating proteins implicated in health and diseases","volume":"13","author":"Bailly","year":"2021","journal-title":"Cancers"},{"key":"B19","doi-asserted-by":"publisher","first-page":"16079","DOI":"10.1038\/mtm.2016.79","article-title":"Impact of intravenous infusion time on AAV8 vector pharmacokinetics, safety, and liver transduction in cynomolgus macaques","volume":"3","author":"Greig","year":"2016","journal-title":"Mol Ther - Methods Clin Dev"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.246","article-title":"Systematic evaluation of AAV vectors for liver directed gene transfer in murine models","volume":"18","author":"Wang","year":"2010","journal-title":"Mol Ther"},{"key":"B21","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ymthe.2006.03.008","article-title":"Analysis of Tumors Arising in Male B6C3F1 Mice with and without AAV Vector Delivery to Liver","volume":"14","author":"Bell","year":"2006","journal-title":"Mol Ther"},{"key":"B22","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4939-7374-3_18","article-title":"AAV6 vector production and purification for muscle gene therapy","volume-title":"Duchenne muscular dystrophy","author":"Halbert","year":"2018"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2022.06.015","article-title":"Assessment of joint pharmacokinetics and consequences for the intraarticular delivery of biologics","volume":"348","author":"Siefen","year":"2022","journal-title":"J Control Release"},{"key":"B24","doi-asserted-by":"publisher","first-page":"101211","DOI":"10.1016\/j.omtm.2024.101211","article-title":"Rationally engineered novel AAV capsids for intra-articular gene delivery","volume":"32","author":"Li","year":"2024","journal-title":"Mol Ther - Methods Clin Dev"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.035063","article-title":"Enhanced gene transfer to arthritic joints using adeno-associated virus type 5: implications for intra-articular gene therapy","volume":"64","author":"Adriaansen","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1089\/humc.2015.009","article-title":"Safety, biodistribution, and efficacy of an AAV-5 vector encoding human interferon-beta (ART-I02) delivered via intra-articular injection in rhesus monkeys with collagen-induced arthritis","volume":"26","author":"Bevaart","year":"2015","journal-title":"Hum Gene Ther Clin Dev"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-131417","article-title":"Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX","volume":"112","author":"Sun","year":"2008","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3390\/pharmaceutics11030129","article-title":"Challenges and recent progress in oral drug delivery systems for biopharmaceuticals","volume":"11","author":"Homayun","year":"2019","journal-title":"Pharmaceutics"},{"key":"B29","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1136\/gutjnl-2019-318281","article-title":"Adeno-associated virus in the liver: natural history and consequences in tumour development","volume":"69","author":"La Bella","year":"2020","journal-title":"Gut"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1177\/01926233231201408","article-title":"An overview of nonclinical and clinical liver toxicity associated with AAV gene therapy","volume":"51","author":"Whiteley","year":"2023","journal-title":"Toxicol Pathol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00082\/abstract","article-title":"Immune responses to AAV-vectors, the glybera example from bench to bedside","volume":"5","author":"Ferreira","year":"2014","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3300548","article-title":"Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia","volume":"5","author":"Monahan","year":"1998","journal-title":"Gene Ther"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2006.05.004","article-title":"Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B","volume":"14","author":"Jiang","year":"2006","journal-title":"Mol Ther"},{"key":"B34","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/4743","article-title":"Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector","volume":"5","author":"Herzog","year":"1999","journal-title":"Nat Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"20150","DOI":"10.1038\/srep20150","article-title":"A Dual Target-directed Agent against Interleukin-6 Receptor and Tumor Necrosis Factor \u03b1 ameliorates experimental arthritis","volume":"6","author":"Kim","year":"2016","journal-title":"Sci Rep"},{"key":"B36","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1084\/jem.20160801","article-title":"PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity","volume":"214","author":"Juneja","year":"2017","journal-title":"J Exp Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2010.245","article-title":"Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors","volume":"22","author":"Gray","year":"2011","journal-title":"Hum Gene Ther"},{"key":"B38","doi-asserted-by":"publisher","first-page":"939","DOI":"10.3892\/etm.2021.10371","article-title":"Applicability and implementation of the collagen\u2212induced arthritis mouse model, including protocols (Review)","volume":"22","author":"Luan","year":"2021","journal-title":"Exp Ther Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20030016","article-title":"Cytosolic phospholipase A2\u03b1\u2013deficient mice are resistant to collagen-induced arthritis","volume":"197","author":"Hegen","year":"2003","journal-title":"J Exp Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-013-2713-4","article-title":"Macrophage-derived, macrophage migration inhibitory factor (MIF) is necessary to induce disease in the K\/BxN serum-induced model of arthritis","volume":"33","author":"Singh","year":"2013","journal-title":"Rheumatol Int"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1527858\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T05:12:50Z","timestamp":1738559570000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1527858\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,3]]},"references-count":40,"alternative-id":["10.3389\/fimmu.2025.1527858"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1527858","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,3]]},"article-number":"1527858"}}